Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Vassiliki Galea"'
Autor:
Patrick Van Dreden, Jean François Bernaudin, Elisabeth Mbemba, Mouna Sassi, Max Japcowitz, Grigoris T. Gerotziafas, Jawed Fareed, Mohamed Hatmi, Jean Pierre Lotz, Amir Khaterchi, Vassiliki Galea, Marie-Paule Roman, Ismail Elalamy
Publikováno v:
Current Vascular Pharmacology. 12:893-902
Low molecular weight heparins (LMWHs) and fondaparinux are widely used for prophylaxis and treatment of venous thromboembolic disease in cancer patients. However, the optimization of the antithrombotic treatment especially in patients with adenocarci
Autor:
Dimitrios Th. Kremastinos, Theodoros Theodoridis, Vasiliki Christopoulou-Cokkinou, Helen Triantafyllidi, Matina Koutroumbi, Maria Anastasiou-Nana, John Lekakis, Vassiliki Galea
Publikováno v:
Journal of the Renin-Angiotensin-Aldosterone System, Vol 14 (2013)
Introduction: Hypertension links to a prothrombotic state driven by endothelial dysfunction, reduced fibrinolytic potential and platelet hyperactivity. We hypothesized that ramipril treatment would favourably modify the haemostatic response to a subm
Autor:
Patrick Van Dreden, Amir Khaterchi, Ismail Elalamy, Hela Baccouche, Mouna Sassi, Claudie Prengel, Vassiliki Galea, Mohamed Hatmi, Jean François Bernaudin, Grigoris T. Gerotziafas, Elisabeth Mbemba
Publikováno v:
Thrombosis Research. 129:779-786
Cancer histology influences the risk of venous thromboembolism and tissue factor (TF) is the key molecule in cancer-induced hypercoagulability. We investigated the relation between TF expression by pancreatic and breast cancer cells (BXPC3 and MCF7 r
Publikováno v:
Sang thrombose vaisseaux. 21:014-026
L’amelioration de nos connaissances sur les mecanismes de la relation reciproque existant entre le cancer et la thrombose a permis de mieux comprendre le role majeur des acteurs de l’hemostase dans la progression tumorale et l’interet du traite
Autor:
Mouna Sassi, Ismail Elalamy, Mohamed Hatmi, Vassiliki Galea, Hela Baccouche, Grigoris T. Gerotziafas, Mourad Chaari, Meyer Michel Samama
Publikováno v:
Thrombosis Research. 129:101-103
Autor:
Patrick Van Dreden, Hela Ketatni, Racem Bouzguenda, Choumous Kallel, Ines Ayadi, Jamel Daoud, Amir Khaterchi, Lilia Ghorbal, Mounir Frikha, Aurélie Rousseau, Grigoris T. Gerotziafas, Joseph Gligorov, Vassiliki Galea, Jean Pierre Lotz, Martin Quinn, Eleftheria Lefkou, Ismail Elalamy, Fatoumata Sidibe, Mohamed Hatmi, Mourad Chaari
Publikováno v:
BMC Cancer
BMC Cancer, 2014, 14, pp.991. ⟨10.1186/1471-2407-14-991⟩
BMC Cancer, BioMed Central, 2014, 14, pp.991. ⟨10.1186/1471-2407-14-991⟩
BMC Cancer, 2014, 14, pp.991. ⟨10.1186/1471-2407-14-991⟩
BMC Cancer, BioMed Central, 2014, 14, pp.991. ⟨10.1186/1471-2407-14-991⟩
International audience; BackgroundIn breast cancer patients routine thromboprophylaxis is not recommended but individualized risk assessment is encouraged. The incorporation of hypercoagulability biomarkers could increase the sensitivity of risk asse
Autor:
Grigoris T. Gerotziafas, Mohamed Hatmi, Francoise Robert, Amir Khaterchi, Vassiliki Galea, Ismail Elalamy
Publikováno v:
Platelets. 24(6)
Heparin-induced thrombocytopenia (HIT) is a potentially lethal adverse effect of heparin therapy. Accurate and rapid HIT laboratory diagnosis when HIT is suspected is crucial. The combination of an immunological assay with a functional test improves
Autor:
E.M. d'Argent, Aurélie Rousseau, Vassiliki Galea, M. Comtet, H. Ketatni, J.-M. Antoine, Ismail Elalamy, S. Bouffard, G.T. Gerotziafas, Patrick Vandreden
Publikováno v:
Thrombosis Research. 131:S100-S101
Autor:
Emmanuelle Mathieu d'Argent, Patrick Van Dreden, Marjorie Comtet, Vassiliki Galea, Hela Ketatni, Matthieu Grusse, Jean-Marie Antoine, Severine Bouffard, Aurélie Rousseau, Elmina Lefkou, Ismail Elalamy, Grigoris T Gerotziafas
Publikováno v:
Blood. 122:3630-3630
Introduction Women undergoing assisted reproductive techniques (ART) are given gonadotrophins to promote the development of multiple follicles within their ovaries. This treatment may be associated with a risk of ovarian hyperstimulation syndrome and
Autor:
Dimitra Karipidi, Vassiliki Galea, Ismail Elalamy, Patrick Van Dreden, Ilias Evmorfiadis, Grigoris T. Gerotziafas, Severin Bouffard, Amir Kartechi, Marie-Paule Roman
Publikováno v:
Blood. 122:3631-3631
Background Clopidogrel is cornerstone treatment for atherothrombotic patients. The incidence of recurrent thrombotic events raises up to 10% of patients on treatment with clopidogrel. Intestinal absorption via the glycoproteine ABCB1, bioactivation b